secwatch.observer — SEC 8-K summary
======================================

Issuer:     AGIOS PHARMACEUTICALS, INC. (AGIO)
CIK:        0001439222
Form:       8-K
Filed at:   2025-05-01T23:59:59+00:00
Accession:  0001439222-25-000034
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Agios Q1 PYRUKYND revenue $8.7M; PDUFA Sept 7 for thalassemia; net loss $89.3M
------------------------------------------------------------------------------

- PYRUKYND net revenue $8.7M in Q1 2025 vs $8.2M in Q1 2024; 136 patients on therapy.
- FDA accepted sNDA for thalassemia with PDUFA goal date September 7, 2025; no advisory committee planned.
- Phase 3 RISE UP in sickle cell disease topline results expected late 2025; potential US launch in 2026.
- Net loss $89.3M in Q1 2025 vs $81.5M in Q1 2024; cash and securities $1.4B as of March 31, 2025.
- Krishnan Viswanadhan appointed Chief Corporate Development and Strategy Officer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1439222/000143922225000034/0001439222-25-000034-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1439222/000143922225000034/agio-20250501.htm
  HTML page:      https://secwatch.observer/filing/0001439222-25-000034

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer